This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Airoldi, I. Articles by Pistoia, V. Search for Related Content PubMed PubMed Citation Articles by Airoldi, I. Articles by Pistoia, V.

Methylation of the IL-12Rß2 Gene as Novel Tumor Escape Mechanism for Pediatric B-Acute Lymphoblastic Leukemia Cells

¹ Laboratory of Oncology, G. Gaslini Institute; ² Animal Model Facility, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; ³ Department of Oncology and Neurosciences and Center of Excellence on Aging, G. D'Annunzio University, Chieti, Italy; and ⁴ Division of Hematology Oncology, Department of Pediatrics, University of Padova, Padova, Italy

Requests for reprints: Irma Airoldi, Laboratory of Oncology, G. Gaslini Institute, Largo G. Gaslini 5, 16148 Genova, Italy. Phone: 39-10-5636342; Fax: 39-10-3779820; E-mail: irmaairoldi{at}ospedale-gaslini.ge.it.

Previous studies have shown that the interleukin-12 receptor ß2 (IL-12Rß2) gene is expressed in normal naive, germinal center and memory B cells but not in their malignant counterparts. The aim of this study was to investigate (i) whether the IL-12Rß2 gene is silenced in B-cell acute lymphoblastic leukemia (B-ALL) cells, and (ii) what the functional implications of such silencing for tumor growth are. Here, we show that although mature B cells expressed both chains of the IL-12R, normal pro-B and pre-B cells failed to express the IL-12Rß2 chain. Similarly, primary tumor cells from pediatric pro-B, early pre-B, and pre-B ALL (30 cases) did not express the IL-12Rß2 chain. IL-12Rß2 gene silencing in B-ALL was found to depend on methylation of a CpG island in exon 1. Such methylation was not detected in normal early B cells that when differentiated into mature B cells expressed the IL-12Rß2 gene. Detection of IL-12Rß2 mRNA and protein in the tumorigenic 697 pre-B-ALL cell line allowed to perform functional experiments in severe combined immunodeficient/nonobese diabetic mice receiving 697 cells with or without human recombinant IL-12 (hrIL-12). hrIL-12 administration reduced tumor growth and metastasis through antiproliferative and proapoptotic rather than antiangiogenic, activities.

In conclusion, epigenetic silencing of the IL-12Rß2 gene represents a novel mechanism of tumor escape for B-ALL cells. (Cancer Res 2006; 66(8): 3978-80)

This article has been cited by other articles:

				V. Pistoia, C. Cocco, and I. Airoldi Interleukin-12 Receptor {beta}2: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies J. Clin. Oncol., October 1, 2009; 27(28): 4809 - 4816. [Abstract] [Full Text] [PDF]

				D. M. Lucas, R. B. Edwards, G. Lozanski, D. A. West, J. D. Shin, M. A. Vargo, M. E. Davis, D. M. Rozewski, A. J. Johnson, B.-N. Su, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo Blood, May 7, 2009; 113(19): 4656 - 4666. [Abstract] [Full Text] [PDF]

				I. Airoldi, C. Cocco, N. Giuliani, M. Ferrarini, S. Colla, E. Ognio, G. Taverniti, E. Di Carlo, G. Cutrona, V. Perfetti, et al. Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target Blood, August 1, 2008; 112(3): 750 - 759. [Abstract] [Full Text] [PDF]